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Immunity raised by recent European 
subtype 1 PRRSV strains allows better 
replication of East European subtype 3 PRRSV 
strain Lena than that raised by an older strain
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Lars E. Larsen2 and Hans J. Nauwynck1
Abstract 
Stable spatial distribution of porcine reproductive and respiratory syndrome (PRRSV)-1 subtypes in Europe is accom-
panied by a strong population immunity induced by local PRRSV strains. In the present study, it was examined if 
the immunity induced by three West European subtype 1 PRRSV strains (2007 isolate 07V063 and 2013 isolates 
13V091 and 13V117) offers protection against the highly virulent East European subtype 3 PRRSV strain Lena. The 
number of fever days was greater (p < 0.05) in the control group (7.6 ± 1.7 days) compared to the immune groups 
(07V063-immune: 4.0 ± 1.2 days, 13V091-immune: 4.6 ± 1.1 days, 13V117-immune: 4.0 ± 2.9 days). In all groups, 
protection was characterized by reduction (p < 0.05) of AUC values of nasal shedding (control: 14.6, 07V063-immune: 
3.4, 13V091-immune: 8.9, 13V117-immune: 8.0) and viremia (control: 28.1, 07V063-immune: 5.4, 13V091-immune: 
9.0, 13V117-immune: 8.3). Reduction of respiratory disease, nasal shedding (mean AUC and mean peak values) and 
viremia (mean AUC and mean peak values) was more pronounced in 07V063-immune (p < 0.05) than in 13V091-
immune and 13V117-immune animals. Inoculation with subtype 1 PRRSV strains caused priming of the Lena-specific 
virus neutralization antibody response. Upon challenge with Lena, we observed a very strong serological booster 
effect for neutralizing antibodies against strains used for the first inoculation. Our results indicate that inoculation with 
subtype 1 PRRSV strains can partially protect against antigenically divergent subtype 3 strains. The lower protection 
level elicited by recently isolated subtype 1 PRRSV strains may impair the outcome of the spatial expansion of subtype 
3 strains from East Europe to West Europe.
© 2016 Trus et al. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://
creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided 
you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate 
if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/
zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Introduction
Porcine reproductive and respiratory syndrome virus 
(PRRSV) is prevalent in most swine farms worldwide, 
and is a major cause of economic losses and animal suf-
fering. Current genetic analysis of a number of European 
genotype PRRSV-1 strains reveals the existence of four 
different subtypes [1]. In Europe, a geographical demar-
cation exists between areas of low (Western and Central 
Europe) and high (Eastern Europe) PRRSV-1 diversity 
[1]. New Belgian PRRSV-1 variants still belong to sub-
type 1, but genetic changes have led to an increase in 
virulence and pathogenicity [2]. This drift has resulted 
in further economic losses in the swine industry in 2013 
and 2014. Stability of the spatial distribution of different 
PRRSV subtypes in Europe allows us to continue using 
the term “East European subtypes” for subtypes 2, 3 and 
4. However, there is a potential risk that East European 
subtypes, which are genetically and antigenically distinct 
from Pan-European subtype 1 viruses and are even more 
virulent/pathogenic, could emerge in Western and Cen-
tral Europe, leading to a real catastrophe [1, 3, 4]. The role 
of existing herd immunity in keeping subtypes 2, 3 and 4 
out of Western and Central Europe is of great interest.
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Active immunization is currently the only widely avail-
able and approved way to control PRRS-related prob-
lems in swine herds worldwide. The existence of different 
PRRSV subtypes requires vaccines that induce a strong 
cross-protective immune response. In a recent publica-
tion, it was demonstrated that the PRRSV-1 subtype 1 
vaccine strain modified live virus (MLV)-DV (GenBank: 
KJ127878), which is closely related to the old prototype 
virus LV (98.4% identity of full genome sequences) (Gen-
Bank: M96262), was able to give partial clinical and viro-
logic protection against PRRSV-1 subtype 3 strain Lena 
[3]. With the appearance of genetically more distant 
PRRSV strains, the question raised as to what degree 
these strains induce a protective immunity against 
PRRSV Lena.
In the present study, the level of protection against 
European PRRSV subtype 3 strain Lena was examined in 
animals immunized with one old and two recent subtype 
1 PRRSV-1 strains.
Materials and methods
Animals, experimental design and inoculation viruses
Twenty conventional pigs were obtained from a PRRS-
negative farm. All animals were housed in separate sta-
bles in a biosafety level 2 (BSL2) facility at the Faculty of 
Veterinary Medicine, Ghent University, Belgium. No rel-
evant pathogens (PRRSV, SIV, PCV2) were detected in 
the animals.
Pigs were randomly divided into four groups with 
five animals per group (07V063, 13V091, 13V117, and a 
mock-inoculated control group). Two consecutive inoc-
ulations were performed in this experiment. Pigs were 
11  weeks old at the first inoculation and 18  weeks old 
at the second inoculation. Inoculations were performed 
intranasally using a 2  ×  105 tissue culture infectious 
dose (TCID) with a 50% end point (TCID50) PRRSV. The 
07V063 group was inoculated with the third passage of 
07V063 strain: the 13V091 group with the third passage 
of 13V091 strain; and the 13V117 group with the sec-
ond passage of 13V117 strain; all propagated in porcine 
alveolar macrophages (PAMs). These subtype 1 PRRSV-1 
strains were isolated from different Belgian farms in 
2007 (07V063) and 2013 (13V091 and 13V117). Subtype 
1 PRRSV 07V063 strain is a mildly pathogenic Belgian 
strain [2, 4]. Newly isolated strains originated from farms 
with animals experiencing endemic respiratory disorders 
in nursery pigs (13V091 and 13V117) [2]. The control 
group was inoculated intranasally using 1 mL phosphate-
buffered saline (PBS) per nostril.
Seven weeks after the first inoculation all four groups 
were inoculated with the PRRSV Lena strain (forth pas-
sage propagated in PAMs). Lena is a highly pathogenic 
East European subtype 3 PRRSV strain isolated from 
aborted fetuses on a Belarusian farm [3–5]. Individual 
sterile syringes and plastic cannulas (Jorgenson Labs J12) 
were used for intranasal virus inoculation.
The sequences of 07V063, 13V091, 13V117 and Lena 
were downloaded from GenBank (GenBank: GU737264, 
KT159248, KT159249, JF802085). Alignment and phylo-
genetic analysis were performed using the Mobyle@Pas-
teur web bioinformatics framework [6].
Clinical and pathological examinations
Clinical monitoring was performed on a daily basis from 
3 days before challenge until 21 days post-challenge (dpc). 
Local parameters included respiratory disorders, discol-
oration of ears, presence or absence of periocular edema, 
and diarrhea. Systemic parameters included rectal tem-
perature (with the threshold for fever set at 39.5 °C) and 
liveliness. Local parameters and liveliness were expressed 
as a score at the animal level, whereas diarrhea was eval-
uated on a group level. The respiratory scoring system 
was adapted from Karniychuk et al. [4].
After euthanasia at 35 dpc, lungs were collected and a 
numerical score was given based on the observed mac-
roscopic lung lesions. This score was used to estimate the 
percentage of lungs affected by pneumonia, as previously 
described [7].
Virus titration
Nasal secretions were collected at 0, 3, 5, 7, 10, 14, 21, 
28 and 35 dpc using sterile swabs (COPAN 160C, Copan 
Italia SpA). One swab was used per nostril and per pig, 
and the two swabs were pooled. One mL of transport 
medium was added and after vortexing (1  h, 4  °C) the 
supernatant was collected and stored at −70 °C for virus 
titration. Transport medium was based on buffer solution 
[1× Dulbecco’s PBS (DPBS) with 0.9 mM CaCl2, 0.5 mM 
MgCl2 × 6H2O and 20 mg/L phenol red] supplemented 
with 10% fetal calf serum (FCS) and a mixture of antibi-
otics (1000 IU/mL penicillin, 1 mg/mL streptomycin and 
0.5  mg/mL gentamycin). Virus titers in the supernatant 
and serum were determined by titration on PAMs col-
lected from PRRSV negative pigs, as previously described 
[8]. The monoclonal antibody 13E2 against the nucle-
ocapsid protein of PRRSV was used to detect PRRSV-
infected cells. Plain swabs were weighed before and after 
swabbing, and viral titers were calculated per 100 mg of 
secrete [4]. Fifty percent endpoint titers were calculated 
by the Reed–Muench method [9].
Serological examinations
Blood was collected at 0, 3, 5, 7, 10, 14, 21, 28 and 35 
dpc by puncture of the vena cava cranialis, and serum 
samples were prepared after centrifugation (10  min, 
1800  g, 4  °C). PRRSV-specific antibodies were detected 
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by the immunoperoxidase monolayer assay (IPMA), and 
PRRSV-specific neutralizing antibodies were titrated 
using the virus neutralization (VN) test on MARC-145 
cells, as previously described [10]. Serum samples were 
heat-inactivated for 30 min at 56 °C prior to testing. The 
PRRSV strain Lena was used as an antigen in IPMA and 
VN assays. Additional VN assays were performed with 
PRRSV strains 07V063, 13V091 and 13V117 to detect 
neutralizing antibodies in animals immunized with the 
respective strains.
Statistical analysis
Serological titers (IPMA and VN), as well as viral loads, 
were log-transformed prior to analysis. Samples test-
ing negative were assigned a value corresponding to half 
the minimum detectable titer. Gross pathology scores 
and area under the curve (AUC) were analyzed using 
the non-parametric Kruskal–Wallis test with Dunn’s 
post-test. Statistical analysis of continuous data was per-
formed using repeated-measures two-way analysis of 
variance (rANOVA), with Bonferroni’s post-test. Results 
were considered to be significantly different at p < 0.05. 
All data were expressed as the mean value  ±  standard 
deviation (SD).
Results
Genetic relationship between subtype 1 strains and East 
European subtype 3 PRRSV strains
A low level of identity was calculated between the pair-
wise distances of full genome sequences of the PRRSV 
subtype 3 Lena strain and the PRRSV subtype 1 strains 
07V063 (79.9%), 13V091 (79.6%) and 13V117 (79.8%) 
(Figure 1).
Phylogenetic analysis of full genome sequences 
revealed a high identity level (99.9%) between the 
07V063 and 13V117 strains (Figure 1). Non-synonymous 
nucleotide substitutions resulted in eight different amino 
acids located in non-structural protein (nsp) 1 (V140M), 
nsp2 (H786L, G1300S), nsp7 (S2192N), nsp9 (M72I, 
M266V), GP3 (N253H) and GP4 (Q72P). Two were 
located in putative antigenic epitopes [11–13]. Q72P was 
found in the B cell ES12 epitope and neutralizing anti-
genic region (NAR) GP4.16 [11, 12]. N253H was found in 
NAR GP3.62 [12].
Clinical signs and pathological examination
Body temperature and respiratory disease scores are rep-
resented in Figure 2. Fever was observed after challenge 
with PRRSV Lena in animals from 2 to 11 dpc in the 
control group, from 3 to 9 dpc in the 07V063-immune 
group, from 3 to 7 dpc in the 13V091-immune group, 
and from 3 to 8 dpc in the 13V117-immune group. The 
number of fever days was higher (p < 0.05) in the control 
group (7.6 ± 1.7 days) compared to the immune groups 
(07V063-immune: 4.0  ±  1.2  days, 13V091-immune: 
4.6  ±  1.1  days, 13V117-immune: 4.0  ±  2.9  days). Sig-
nificantly higher mean temperature (p  <  0.01) was 
observed in the 13V091-immune group (40.9 ±  0.5  °C) 
compared to the control group (39.5 ± 0.7 °C) at 3 dpc. 
Mean AUC values had no significant differences between 
the groups (control group: 4.5  ±  2.9, 07V063-immune 
group: 2.4  ±  0.9, 13V091-immune group: 3.6  ±  1.2, 
13V117-immune group: 2.5 ± 2.6). In all groups, animals 
showed no diarrhea, nasal discharge, coughing, or ear 
discoloration.
Animals from the 07V063-immune group showed sig-
nificantly lower mean clinical scores for respiratory dis-
ease than control animals at 3 dpc (p < 0.05). One animal 
from the 13V091-immune group, and three animals from 
the control and 13V117-immune groups had clinical 
scores >1. No animals from the 07V063-immune group 
had such a level of respiratory disease.
The extent of macroscopic pneumonia was not sig-
nificantly different (p  >  0.05). The lowest values were 
observed in the 07V063-immune group (control group: 
1.6 ± 1.8%, 07V063-immune group: 0.3 ± 0.4%, 13V091-
immune group: 1.0  ±  2.2%, 13V117-immune group: 
1.5 ± 1.4%).
Virological analysis
Nasal shedding (Figure  3) was observed from 3 dpc 
in the control, 13V091-immune and 13V117-immune 
animals, and from 5 dpc in animals from the 07V063-
immune group. At 5–7 dpc, shedding was found in all 
animals except for one pig from the 13V117-immune 
group. A peak mean virus titer was reached at 3 (control 
group: 104.3 TCID50/100 mg) or 5 dpc (07V063-immune 
group: 102.4 TCID50/100  mg, 13V091-immune group: 
104.6 TCID50/100  mg, 13V117-immune group: 104.1 
Figure 1 A phylogenetic tree of circulating Belgian virus 
isolates. Molecular phylogenetic analysis of full genome nucleotide 
sequences was constructed using the Neighbor-Joining method. 
Phylogenetic relationships were estimated using the Clustal Omega 
method. Prototype subtype 1 (LV) and subtype 3 (Lena) PRRSV-1 
strains, vaccine parental (DV) and attenuated (MLV-DV) PRRSV-1 
strains were added to phylogenetic tree. The optimal tree is drawn 
to scale. Numbers indicate bootstrap values of 100 replicates. Strain 
nomenclature is as follows: name or diagnostic number/year of isola-
tion/country of origin/GenBank accesion number.
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Figure 2 Body temperature and respiratory disease scoring after challenge. Lines represent the mean value in each group. Dotted line 
gives the mean values of the control group. Temperatures of ≥39.5 °C were considered as fever (dashed line). Respiratory disease scores ranged 
from 0 to 6: 0 = normal; 1 = mild dyspnea and/or tachypnea when stressed; 2 = mild dyspnea and/or tachypnea at rest; 3 = moderate dysp-
nea and/or tachypnea when stressed; 4 = moderate dyspnea and/or tachypnea at rest; 5 = severe dyspnea and/or tachypnea when stressed; 
6 = severe dyspnea and/or tachypnea at rest. Asterisk represents statistically discernible differences from the control (p < 0.05).
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Figure 3 PRRSV titers in nasal secretions and sera after challenge and clustering of individual AUCs. Lines represent the mean titer in 
each group. Dotted line gives the mean values for the control group. Dashed line gives the detection limit for virus titration. Asterisk represents 
statistically discernible differences from the control (p < 0.05).
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TCID50/100  mg). Significantly lower mean virus titers 
were detected at 3 dpc in 07V063-immune and 13V117-
immune animals, and at 7 dpc in 13V091-immune ani-
mals compared to control pigs. Nasal shedding stopped 
in all animals by 10 dpc. The mean AUC was significantly 
lower (p  <  0.05) in the 07V063-immune group than in 
the control group (control group: 14.6  ±  5.6, 07V063-
immune group: 3.4  ±  3.4, 13V091-immune group: 
8.9 ± 6.1, 13V117-immune group: 8.0 ± 6.1) (Figure 3).
Viremia was detected from 3 dpc in all animals, 
except for one 13V117-immune animal and in three 
animals from the 07V063-immune group (Figure  3). 
Virus was isolated from all animals at 5–7 dpc. A peak 
mean virus titer was observed at 10 dpc (control group: 
104.0 TCID50/mL), 5 dpc (07V063-immune group: 102.5 
TCID50/mL, 13V117-immune group: 103.1 TCID50/mL) 
or 3 dpc (13V091-immune group: 103.8 TCID50/mL). Sig-
nificantly higher virus titers were found in the control 
group compared to all immune groups at 7 and 10 dpc 
(p  <  0.001). No virus was isolated from serum samples 
starting from 28 dpc (control group), 10 dpc (07V063-
immune and 13V117-immune groups) or 7 dpc (13V091-
immune group). The mean AUC was significantly higher 
(p  <  0.05) in control animals than in 07V063-immune 
and 13V117-immune groups (control group: 28.1 ± 11.0, 
07V063-immune group: 5.4  ±  4.4, 13V091-immune 
group: 9.0  ±  1.5, 13V117-immune group: 8.3  ±  4.8). 
The relationship between the AUCs of nasal shedding 
and viremia was found to be significant (Spearman’s 
rho = 0.62, p = 0.0038) (Figure 3).
Serology
Prior to challenge, serum samples animals in the control 
group were negative according to the IPMA (Figure  4). 
Animals from all immune groups had high titers of virus-
specific antibodies (27.3–215.3). The antibody titers in 
immune and control animals were not different from 10 
dpc (p > 0.05).
VN antibodies against subtype 1 PRRSV strains 
(07V063, 13V091 and 13V117) were detected at 0 dpc in 
five animals from the 07V063-immune group, four ani-
mals from the 13V091-immune group and five out of five 
animals from the 13V117-immune group (Figure 4). Indi-
vidual VN antibody titers increased fourfold at 7 dpc in 
07V063, 13V091 and 13V117-immune groups.
Prior to challenge, VN antibodies against the subtype 
3 PRRSV Lena strain were detected only in one animal 
from the 13V091-immune group (Figure  4). Upon chal-
lenge, two out of five animals in the control group had 
a detectable level of VN antibodies at 21 and 28 dpc. In 
immune groups, the majority of animals (>50%) demon-
strated a VN antibody response against Lena strain dur-
ing the experiment: 07V063-immune group: five animals, 
13V091-immune group: four animals, 13V117-immune 
group: three animals).
Discussion
A high rate of genetic and antigenic variability among 
PRRSV isolates hampers effective prevention and control 
of the disease by the use of commercial vaccines. Rising 
diversity of PRRSV makes it impossible to have a refer-
ence isolate representing the whole country or a part of 
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Figure 4 PRRSV-specific IPMA and VN antibody titers after 
challenge. The PRRSV Lena strain was used as an antigen in IPMA 
assay. VN antibody titers were tested against subtype 1 (07V063, 
13V091 and 13V117, respectively) and against subtype 3 PRRSV (Lena) 
strains. Lines represent the mean titer in each group. Dashed line 
gives detection limit for the test. Letters (a: 13V091-immune group, b: 
13V117-immune group, c: 07V063-immune group) represent statisti-
cally significant differences from the control (p < 0.05).
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Europe. In the present study, we examined the protection 
of the immunity induced by an old and two new West 
European subtype 1 PRRSV strains effective against a 
heterologous East European subtype 3 virus challenge. 
The three subtype 1 isolates that were used in this study 
(07V063, 13V091 and 13V117) differed strongly geneti-
cally from subtype 3 PRRSV strain Lena. Detailed reports 
on their genetic backgrounds and the pathogenicity of 
these subtype 1 and 3 PRRSV strains have been previ-
ously published [1–5].
As an outcome of this study, protection in all immu-
nized groups was characterized by reduction of fever 
length (p  <  0.05), nasal shedding (mean AUC) and 
viremia (mean AUC). Reduction of respiratory disease, 
nasal shedding (mean AUC and mean peak values) and 
viremia (mean AUC and mean peak values) was more 
pronounced (p  <  0.05) in animals inoculated with the 
older, low pathogenic strain (07V063-immune group). 
Subtype 1 PRRSV 13V091 and 13V117 strains were iso-
lated in 2013, 6  years later than the 07V063 strain. A 
lower level of cross protection caused by immunization 
with the most recent strains, illustrates a negative impact 
of rising evolutional diversity of contemporary PRRSV 
strains on the formation of heterosubtypic immunologi-
cal protection in swine herds, and on the preservation of 
spatial distribution of PRRSV subtypes in Europe.
Cellular immunity and neutralizing antibodies may be 
involved in clearance of the virus after PRRSV infection. 
The latter may correlate with the protective immunity 
against PRRSV [14]. In this study, inoculation of animals 
with subtype 1 PRRSV strains caused priming of Lena-
specific VN antibodies. We observed a faster VN anti-
body response upon challenge with PRRSV Lena in the 
07V063-immune group (50% of the animals formed a VN 
antibody response at 3 dpc) compared to the other groups 
(control group: >35 dpc, 13V091-immune group: 10 dpc, 
13V117-immune group: 21 dpc). Moreover, only in the 
07V063-immune group was a VN antibody response 
against PRRSV Lena detected in all animals. Faster VN 
antibody response in animals from the 07V063-immune 
group coincides with better clinical and virologic protec-
tion. Thus, VN antibody response upon challenge may be 
considered as an important factor in the development of 
immunologic protection.
Upon challenge with subtype 3 PRRSV Lena, a booster 
effect was observed against strains used for the first inoc-
ulation. Analysis of putative antigen recognition domains 
revealed conservation for two of them [11–13]. One neu-
tralizing antigenic region (GP2.30) was conserved in all of 
the strains used in this study (EHSGQAAWKQVV) [12]. 
One epitope (HGAGNMGVDGSVWDF) from nsp9 with 
T-cell antigen reactivity was conserved in Lena, 07V063 
and 13V117 strains [13]. Although subtype 3 strain Lena 
is genetically and antigenically quite different from the 
subtype 1 PRRSV strains (07V063, 13V091 and 13V117), 
neutralizing epitopes (e.g., GP2.30) may stay conserved 
and provide the VN antibody booster reaction.
Possible exacerbation of clinical effects [15, 16], inten-
sive interstitial pneumonia [17] and increased viremia 
[18] has already been reported in animals immunized 
with DNA, sub-unit, and MLV vaccines against PRRS, 
respectively. We observed that immunization with the 
07V063 strain, compared to the 13V091 and 13V117 
strains, provided substantially better cross-protection 
against the subtype 3 PRRSV Lena strain. In contrast, 
animals from the 13V091-immune group demonstrated 
temporal exacerbation of PRRS disease manifested 
by higher body temperature (p  <  0.001) and viremia 
(p  <  0.05) at 3 dpc. Compared to the 07V063-immune 
group, 13V091-immune animals had a higher body tem-
perature (p  <  0.001), respiratory disease and viremia 
(p < 0.01) at 3 dpc, and higher virus titers in nasal secre-
tions at 3–5 dpc (p  <  0.05). Taken together, these data 
suggest that the immune response against PRRSV might 
be a double-edged sword [19]. On the one hand, it pro-
vides protection against genetically close and distant 
strains, but on the other hand it may activate early repli-
cation after contact by an antibody-dependent enhance-
ment of infectivity (ADEI) process [18]. In the current 
study, genetic relatedness may not be a useful guide to 
accurately predict the level of cross-protection in pigs. 
Further research is needed to assess the mechanism 
involved in the immunopathogenesis of PRRS.
In the present study, immunization of animals with 
subtype 1 PRRSV strains resulted in partial protection, 
and significantly reduced viral replication and clinical 
signs upon inoculation with a heterologous East Euro-
pean subtype 3 PRRSV Lena strain. These results could 
be compared with the outcome of our recent study on 
the efficacy of an attenuated vaccine (Porcilis® PRRS, 
MSD Animal Health) based on the subtype 1 PRRSV 
DV strain (GenBank: KJ127878, KF991509) [3]. PRRSV-
specific IPMA antibody titers after one shot vaccination 
were similar to those observed at 0 dpc in the current 
study. Animals were challenged with subtype 3 PRRSV 
Lena strain in the same way as in this study. Protection 
in the vaccination study was characterized by a similar 
reduction of clinical disease, i.e., reduced fever length 
(p < 0.05) and respiratory distress level (p < 0.05). Viro-
logic parameters showed protection with reduced 
viremia (p < 0.05) and shorter duration of nasal shedding 
(p  <  0.05), and lower AUCs for viremia (p  <  0.05) and 
nasal shedding (p < 0.05) as in the present study. Similarly 
to the current experiment, the majority (>50%) of vac-
cinated animals had detectable levels of VN antibodies 
after challenge (14 dpc for the vaccination at 4 weeks, 28 
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dpc for the vaccination at 7 weeks). Overall, we can con-
clude that parenteral administration of the widely used 
MLV vaccine against PRRS and immunization with sub-
type 1 strains is able to induce a comparable protection 
level against the subtype 3 PRRSV strain Lena.
Immunization of pigs should be used to prevent the 
transmission of recently isolated highly pathogenic 
PRRSV strains. However, currently available commercial 
vaccines based on old type 1 PRRSV strains provide only 
partial protection against genetically different strains 
from the same type [3, 20]. Therefore, the use of live-res-
ident virus inoculation (LVI) may be proposed. This pro-
cedure, which has been evaluated as PRRS management 
tool [19, 21], consists of exposure of naïve gilts prior to 
introducing them into the breeding herd. Although the 
immune response to virulent PRRSV is usually stronger 
than that to attenuated virus [19], the LVI approach can 
increase the risk of further dissemination of field PRRSV 
strains. In addition, higher production losses in breeding 
herds were shown when the LVI method was used com-
pared to farms using MLV vaccines [19]. Therefore, the 
use of MLV vaccines should be preferred for PRRS con-
trol and elimination programs.
The restricted flow of marketable pigs from Eastern 
to Western Europe is keeping the risk of transboundary 
spread of highly pathogenic subtype 3 PRRSV strains 
to a minimum. In our study we investigated the role of 
immunity on the outcome of such spread. Although the 
immunity elicited by all three subtype 1 PRRSV strains 
provides a partial protection against antigenically diver-
gent subtype 3 strains, a lower protection level was 
induced by the two most recently isolated subtype 1 
PRRSV strains (2013) compared to that induced by the 
older strain (2007). The higher replication of a subtype 3 
PRRSV strain in pigs immune after infection with more 
recent strains might result in an easier spatial expansion 
of subtype 3 strains nowadays than in the past.
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